-
Medistim REQUEST Multicenter Registry Study Results to be Presented at AATS in April
The objective for the REQUEST study is to document how often the combination of high-resolution ultrasound imaging and transit time flow measurements (TTFM) performed with Medistim's VeriQC or MiraQ devices will change the surgical procedure.…
Read more -
Results for the Fourth Quarter and Preliminary Results for 2017
Currency neutral sales of own products increased by 31.3 % for the quarter. For 2017, currency neutral growth in sales of own products was 15.7%. EBIT for the quarter ended at MNOK 16.4 (MNOK 9.7),…
Read more -
Medistim joins GE Vingmed Ultrasound and Sensocure in the development of new production technology
Sensocure, GE Vingmed Ultrasound and Medistim have been granted funding of MNOK 14,4 over 3 years from the BIA Health program at the Norwegian Research Council, for the project «Advanced Manufacturing Technologies for High Impact…
Read more -
Results for the Third Quarter 2017
Currency neutral growth of own products is 12.5%. Flow probe sales negatively impacted with MNOK 2.2, however, production of flow probe capacity is improving and backorder is reduced from 500 to 250 probes. Another strong…
Read more -
Results for the Second Quarter 2017
Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…
Read more -
Preliminary findings from the REQUEST registry study presented at the ICC in New York, USA
The REQUEST study is a prospective, multicenter registry with leading cardiac surgery centers from Europe, USA and Canada, led by Coordinating Investigator Professor David Taggart from the University of Oxford. The objective is to study…
Read more -
Medistim has received clearance for sale of MiraQ™ in China
MiraQ™ represents Medistim's most advanced system for ultrasonic surgical guidance and quality assessment used intraoperatively during coronary artery bypass grafting (CABG) as well as vascular and transplant surgery. The system combines state-of-the-art transit time blood…
Read more -
Results for the First Quarter 2017
Sales in the first quarter amounted to MNOK 74.4 (MNOK 65.5), a 13.5 % growth. Currency neutral growth of own products was 20.3 %. Sales from the US increases with 9.6 % in USD. In…
Read more -
Annual Report 2016
Sales for the group in 2016 ended at 268.1 MNOK (251.4 MNOK), a 6.6 % growth. Download full report here: Annual Report Medistim 2016
Read more -
Results for the Fourth Quarter 2016
Currency neutral sales of own products decreased with 3 MNOK or 5.7 % due in part to a back order situation on TTFM flow probes. Currency neutral sales of own products increased with 9.5 %…
Read more
PC: Hold CTRL and press + (plus) to enlarge or - (minus) to shrink.
MAC: Hold CMD and press + (plus) to enlarge or - (minus) to shrink.